Britain is in talks with Oxford and AstraZeneca (AZN.L) for additional doses of their COVID-19 vaccine that has been modified to better target the “beta” coronavirus variant first identified in South Africa, and it will fund trials of the shots.
Britain has previously secured 100 million doses of the vaccine, developed at the University of Oxford and licenced to AstraZeneca, and…
Connect with us on our socials: